Living mapping and living systematic review of Covid-19 studies

Studies registered

3728

Registered studies

1227

Randomized Trials (excluding Traditional Chinese Medicine trials)
690 RCTs recruiting

Results

26913

Records screened

25

Randomized Controlled Trials

16

Non-randomized trial

163

Observational studies

On July 3 we have screened 280 new records.

Several randomized trials were identified this week assessing the effect of Dexamethasone, Colchicine, Hydroxychloroquine, and Chloroquine in addition to a trial evaluating re-Opening of Training Facilities during the COVID-19 pandemic are available on our website. Observational studies assessing Ivermectine, Hydroxychlroquine, Methylprednisolone, steroids and Immunoglobulin are available as well. Risk of bias assessments of all included and analysed studies are published on our website.

Following the publication of an expression of concern by the Lancet (June 3, 2020) regarding the paper by Mandeep Mehra et al—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, and the retraction by 3 of the authors (June 4, 2020), we decided to delete data related to this study from our website

The research mapping has been updated on June 23, 2020 with 49 new registered RCTs identified in the WHO ICTRP.

Follow us on Twitter

To receive updates on our project and research findings, please subscribe to our weekly digest, we will share with you new RCT results and other interesting news.

Our main activities

We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.

Our process is summarized in this figure. For more information on our methods see our protocol here.

This study receives some funding from a grant from the ANR (Agence Nationale de la Recherche).

We encourage all investigators of Randomized Controlled Trials to contact us as soon as they have results available.